Business Wire

SK pharmteco Unites Leading Brands to Create Global Powerhouse in CDMO Services

11.12.2024 15:05:00 CET | Business Wire | Press release

Share

Streamlined Organization Lays Foundation for Company Rebrand

SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving the pharmaceutical and cell & gene therapy industries, today announced the launch of a brand unification initiative. This strategic move brings together the expertise and capabilities of several industry-respected organizations under the unified SK pharmteco brand.

This initiative builds on the legacies of SK biotek, SK biotek Ireland, Center for Breakthrough Medicines, Yposkesi, AMPAC Fine Chemicals, and AMPAC Analytical to create a Contract Development and Manufacturing Organization (CDMO) powerhouse. While these individual brands will continue to operate, they will now be known collectively as SK pharmteco, symbolizing a new era of innovation and growth.

“By uniting under the SK pharmteco banner, we create a stronger, more streamlined organization that delivers a seamless experience for our clients,” said Joerg Ahlgrimm, CEO of SK pharmteco. “Our combined capabilities encompass many services, from early-stage development to commercial manufacturing and state-of-the-art analytical testing. This comprehensive offering empowers us to support our partners throughout the entire drug development lifecycle and, ultimately, quickly provide life-changing therapies to those who need it most.”

Building upon this brand unification, SK pharmteco will unveil a comprehensive rebranding initiative. This transformation will encompass a recently launched new website with a fresh URL, www.skpharmteco.com, along with modern and cohesive visual imagery, and updated email addresses to reflect the unified SK pharmteco brand identity.

“Our rebrand marks a pivotal moment for SK pharmteco, aligning our identity with our mission to deliver transformative medicines to patients and our commitment to providing exceptional service to our customers,” said Liza Rivera, SK pharmteco’s Vice President of Marketing & Communications, who is leading the branding efforts. “Additionally, it reflects our dedication to innovation, collaboration, and excellence as a trusted partner.”

The unified SK pharmteco boasts a robust global footprint with facilities strategically located across North America, Europe, and Asia. This extensive network ensures efficient project management and facilitates close collaboration with clients worldwide.

The company’s expanded service portfolio encompasses:

  • Process development and manufacture of small molecules (APIs intermediates and registered starting materials)
  • Cell and Gene Therapy (CGT) development and manufacturing
  • Analytical development and testing services

About SK pharmteco

SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241211426371/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release

Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c

Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 15:17:00 CET | Press release

Collaboration brings together Argenta's Molecule to Market capabilities and Loyal’s lifespan extension therapeutics with early development of LOY-003 Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candida

NIKE, Inc. Unveils the Next Generation of Innovation Across Performance Sports and Sportswear16.11.2026 15:08:00 CET | Press release

From the next evolution of Nike Air to new Nike Mind and Nike Free footwear, Nike is solving distinct athlete needs — and creating platforms that can bring those breakthroughs to more athletes.New innovations and platforms span running, training, basketball, football and outdoor sports, reflecting Nike's focus on delivering best-in-class performance to athletes across disciplines.Nike is bringing performance innovation into everyday style, reinventing the classics athletes love while introducing new silhouettes, including Project Ride and Nike Morpho X.Much of what Nike is showing arrives over the coming year, with some innovations following later. Watch for more details in the months to come. NIKE, Inc. (NYSE: NKE) is sharing a first look at its next generation of innovation, showcasing new technologies, product platforms and silhouettes across footwear, Sportswear and performance apparel. This press release features multimedia. View the full release here: https://www.businesswire.com

2027 Cocktail Trends Put a Fresh Spin on Classics, Flavor and the Night Out16.11.2026 13:00:00 CET | Press release

The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience The five emerging movements poised to shape cocktail culture in 2027 were unveiled today in the eighth annual Bacardi Cocktail Trends Report published by Bacardi Limited, the world’s largest privately held international spirits company. Created in collaboration with strategic foresight consultancy The Future Laboratory (TFL), the report combines global consumer research, bartender insights, and industry perspectives to explore how the cocktail experience is evolving. The report also reveals the top cocktails Legal Drinking Age (LDA) consumers plan to order at bars and venues worldwide throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116061749/en/ The Bacardi Cocktail Trends Report explores how flavor, hospitality and human recommendations will shape the drinks experience in 2027. “F

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye